Pasar al contenido principal

PROTEINAS SRCR COMO RECEPTORES RECONOCEDORES DE MICROORGANISMOS: UN AMPLIO RASTREO DE INTERACCIONES CON BACTERIAS PATOGENICAS

PCIN-2015-070

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos Programación Conjunta Internacional
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Subdirección General de Proyectos Internacionales
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis

  • Martínez-Florensa, Mario
  • Consuegra-Fernández, Marta
  • Aranda, Fernando
  • Armiger-Borràs, Noelia
  • Di Scala, Marianna
  • Carrasco, Esther
  • Pachón, Jerónimo
  • Vila, Jordi
  • González-Aseguinolaza, Gloria
  • Lozano, Francisco
Sepsis still constitutes an unmet clinical need, which could benefit from novel adjunctive strategies to conventional antibiotic therapy. The soluble form of the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key pathogenic components from Gram-positive and -negative bacteria and shows time- and dose-dependent efficacy in mouse models of monobacterial sepsis. The objective of the present work was to demonstrate the effectiveness of infusing mouse and human sCD6 by different systemic routes, either alone or as adjunctive therapy to gold standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6 mice undergoing high-grade septic shock induced by cecal ligation and puncture (CLP; ≥90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.) route with shCD6 at different doses and time points, either alone or in combination with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Significantly reduced mortality and proinflammatory cytokine levels were observed by i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre- or post-CLP. When using the i.v. route, mice survival was significantly extended by starting shCD6 infusion at later time points post-CLP (up to 6 h after CLP). Significant adjunctive effects on mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained levels (5 to 10 μg/ml) of mouse sCD6 in serum by means of transduction with hepatotropic adeno-associated virus (AAV). Taken together, the data support the conserved antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy in experimental models of complex and severe polymicrobial sepsis., This work was supported by grants from the Spanish Ministerio de Economía y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R), Instituto de Salud Carlos III (ISCIII)-cofinanced by European Development Regional Fund “A way to achieve Europe” ERDF (Spanish Network for Research in Infectious Diseases, REIPI, RD12/0015/0018), and Fundació La Marató TV3 (201319-30-31). F.A. is recipient of a Sara Borrell fellowship (CD15/00016) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Erratum for Martínez-Florensa et al., “Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis”

  • Martínez-Florensa, Mario
  • Consuegra-Fernández, Marta
  • Aranda, Fernando
  • Armiger-Borràs, Noelia
  • Di Scala, Marianna
  • Carrasco, Esther
  • Pachón, Jerónimo
  • Vila, Jordi
  • González-Aseguinolaza, Gloria
  • Lozano, Francisco
Sepsis still constitutes an unmet clinical need, which could benefit from novel adjunctive strategies to conventional antibiotic therapy. The soluble form of the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key pathogenic components from Gram-positive and -negative bacteria and shows time- and dose-dependent efficacy in mouse models of monobacterial sepsis. The objective of the present work was to demonstrate the effectiveness of infusing mouse and human sCD6 by different systemic routes, either alone or as adjunctive therapy to gold standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6 mice undergoing high-grade septic shock induced by cecal ligation and puncture (CLP; ≥90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.) route with shCD6 at different doses and time points, either alone or in combination with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Significantly reduced mortality and proinflammatory cytokine levels were observed by i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre- or post-CLP. When using the i.v. route, mice survival was significantly extended by starting shCD6 infusion at later time points post-CLP (up to 6 h after CLP). Significant adjunctive effects on mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained levels (5 to 10 μg/ml) of mouse sCD6 in serum by means of transduction with hepatotropic adeno-associated virus (AAV). Taken together, the data support the conserved antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy in experimental models of complex and severe polymicrobial sepsis., This work was supported by grants from the Spanish Ministerio de Economía y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R), Instituto de Salud Carlos III (ISCIII)-cofinanced by European Development Regional Fund “A way to achieve Europe” ERDF (Spanish Network for Research in Infectious Diseases, REIPI, RD12/0015/0018), and Fundació La Marató TV3 (201319-30-31). F.A. is recipient of a Sara Borrell fellowship (CD15/00016) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6

  • Casadó-Llombart, Sergi
  • Velasco-de Andrés, María
  • Catalá, Cristina
  • Leyton-Pereira, Alejandra
  • Lozano, Francisco
  • Bosch, Elena
This article belongs to the Special Issue Scavenger Receptors in Inflammation., Pathogens are one of the main selective pressures that ancestral humans had to adapt to. Components of the immune response system have been preferential targets of natural selection in response to such pathogen-driven pressure. In turn, there is compelling evidence showing that positively selected immune gene variants conferring increased resistance to past or present infectious agents are today associated with increased risk for autoimmune or inflammatory disorders but decreased risk of cancer, the other side of the same coin. CD5 and CD6 are lymphocytic scavenger receptors at the interphase of the innate and adaptive immune responses since they are involved in both: (i) microbial-associated pattern recognition; and (ii) modulation of intracellular signals mediated by the clonotypic antigen-specific receptor present in T and B cells (TCR and BCR, respectively). Here, we review available information on CD5 and CD6 as targets of natural selection as well as on the role of CD5 and CD6 variation in autoimmunity and cancer., This research was funded by Spanish Ministerio de Economía y Competitividad (MINECO; SAF-2016-80535-R, PID2019-106658RB-I00 and PCIN-2015-070) co-financed by European Development Regional Fund (ERDF) “A way to achieve Europe”, Agencia Estatal de Investigación (AEI; PID2019-110933GB-I00/AEI/10.13039/501100011033 and CEX2018-000792-M) and Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR; 2017/SGR/1582 and 2017SGR00702) from Generalitat de Catalunya to F.L. and E.B. In addition, S.C.-L., M.V.-d.A., C.C. and A.L.-P. are recipients of fellowships from Ministerio de Educación, Cultura y Deporte (FPU15/02897) MINECO (BES-2014-069237; BES-2017-082107) and Chilean Agencia Nacional de Investigación y Desarrollo (ANID; 2018-72190154), respectively., Peer reviewed